 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Oct 20, 2010 |
| Title |
Cell type-specific induction of mRNA in human B cells and monocytes by IFN-beta |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Compared to primary human monocytes in whole blood cultures, few B cells activated STAT1 in response to stimulation of 2000 IU/ml IFN-beta for 45 minutes. Because activation of STAT1 leads to apoptosis induction, we tested the hypothesis that less pro-apoptotic genes are induced in B cells as compared to monocytes.
Manuscript titled: Major differences in the responses of primary human leukocyte subsets to IFN-beta.
Abstract: Treatment of cell lines with type I IFNs activates the formation of ISGF3 (STAT1/STAT2/ IRF9), which induces the expression of many genes. To study this response in primary cells, we treated fresh human blood with IFN-beta and used flow cytometry to analyze phosphorylated STATs1, 3 and 5 in CD4+ and CD8+ T cells, B cells, and monocytes. The activation of STAT1 was remarkably different among these leukocyte subsets. In contrast to monocytes, CD4+ and CD8+ T cells, few B cells activated STAT1 in response to IFN-beta, a finding that could not be explained by decreased levels of IFNAR2 or STAT1 or enhanced levels of SOCS1 or relevant protein tyrosine phosphatases in B cells. Micro-array and real-time PCR analyses revealed the induction of STAT1-dependent pro-apoptotic mRNAs in monocytes but not in B cells. These data show that ISGF3 or STAT1 homodimers are not the main activators of gene expression in primary B cells of healthy humans. Notably, in B cells and especially in CD4+ T cells, IFN-beta activated STAT5 in addition to STAT3, with biological effects often opposite from those driven by activated STAT1. These data help to explain why IFN-beta increases the survival of primary human B cells and CD4+ T cells, but enhances the apoptosis of monocytes, and also to understand how leukocyte subsets are differentially affected by endogenous type I IFNs during viral or bacterial infections, and by type I IFN treatment of patients with multiple sclerosis, hepatitis or cancer.
|
| |
|
| Overall design |
Undiluted whole blood of 2 healthy individuals (HI) was used, and either stimulated with IFN-beta or left untreated (control) for 3 hrs. After 3 hrs, both B cells and monocytes were isolated from whole blood of the first healthy individual, and only B cells were isolated from whole blood of the second healthy individual.
|
| |
|
| Contributor(s) |
van Boxel-Dezaire AH, Xu Y, Stark GR |
| Citation(s) |
20956346 |
| |
| Submission date |
Jul 29, 2010 |
| Last update date |
Jan 18, 2013 |
| Contact name |
Anette H. van Boxel-Dezaire |
| E-mail(s) |
vanboxa@ccf.org
|
| Phone |
216-445-4478
|
| Fax |
216-444-0512
|
| Organization name |
Cleveland Clinic Foundation
|
| Department |
Molecular Genetics
|
| Lab |
Stark
|
| Street address |
9500 Euclid Avenue
|
| City |
Cleveland |
| State/province |
OH |
| ZIP/Postal code |
44195 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL6104 |
Illumina humanRef-8 v2.0 expression beadchip |
|
| Samples (6)
|
|
| Relations |
| BioProject |
PRJNA131197 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE23307_RAW.tar |
3.4 Mb |
(http)(custom) |
TAR |
| GSE23307_non_normalized.txt.gz |
925.1 Kb |
(ftp)(http) |
TXT |
| Processed data included within Sample table |
|
|
|
|
 |
Less...
More...